Idelalisib plus rituximab boosts survival in relapsed chronic lymphocytic leukemia The Oncology Report NEW ORLEANS – Adding idelalisib to rituximab significantly extends survival in patients with heavily pretreated relapsed chronic lymphocytic leukemia unsuitable for chemotherapy, according to results from Study 116. The primary endpoint of median ... |
